| Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration JS Heier, DM Brown, V Chong, JF Korobelnik, PK Kaiser, QD Nguyen, ... Ophthalmology 119 (12), 2537-2548, 2012 | 2451 | 2012 |
| Intravitreal aflibercept for diabetic macular edema JF Korobelnik, DV Do, U Schmidt-Erfurth, DS Boyer, FG Holz, JS Heier, ... Ophthalmology 121 (11), 2247-2254, 2014 | 958 | 2014 |
| Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six–week results of the VIEW studies U Schmidt-Erfurth, PK Kaiser, JF Korobelnik, DM Brown, V Chong, ... Ophthalmology 121 (1), 193-201, 2014 | 890 | 2014 |
| Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies DM Brown, U Schmidt-Erfurth, DV Do, FG Holz, DS Boyer, E Midena, ... Ophthalmology 122 (10), 2044-2052, 2015 | 611 | 2015 |
| Increasing prevalence of myopia in Europe and the impact of education KM Williams, G Bertelsen, P Cumberland, C Wolfram, VJM Verhoeven, ... Ophthalmology 122 (7), 1489-1497, 2015 | 504 | 2015 |
| Prevalence of refractive error in Europe: the European Eye Epidemiology (E3) Consortium KM Williams, VJM Verhoeven, P Cumberland, G Bertelsen, C Wolfram, ... European journal of epidemiology 30, 305-315, 2015 | 504 | 2015 |
| Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study U Schmidt-Erfurth, B Eldem, R Guymer, JF Korobelnik, RO Schlingemann, ... Ophthalmology 118 (5), 831-839, 2011 | 504 | 2011 |
| Prevalence of age-related macular degeneration in Europe: the past and the future JM Colijn, GHS Buitendijk, E Prokofyeva, D Alves, ML Cachulo, ... Ophthalmology 124 (12), 1753-1763, 2017 | 465 | 2017 |
| Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies JS Heier, JF Korobelnik, DM Brown, U Schmidt-Erfurth, DV Do, E Midena, ... Ophthalmology 123 (11), 2376-2385, 2016 | 411 | 2016 |
| Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials P Mitchell, JF Korobelnik, P Lanzetta, FG Holz, C Pruente, ... British Journal of Ophthalmology 94 (1), 2-13, 2010 | 375 | 2010 |
| Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study JF Korobelnik, FG Holz, J Roider, Y Ogura, C Simader, U Schmidt-Erfurth, ... Ophthalmology 121 (1), 202-208, 2014 | 319 | 2014 |
| VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study FG Holz, J Roider, Y Ogura, JF Korobelnik, C Simader, G Groetzbach, ... British Journal of Ophthalmology 97 (3), 278-284, 2013 | 272 | 2013 |
| Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial M Paques, C Chastang, A Mathis, J Sahel, P Massin, C Dosquet, ... Ophthalmology 106 (5), 932-938, 1999 | 265 | 1999 |
| Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations KB Freund, JF Korobelnik, R Devenyi, C Framme, J Galic, E Herbert, ... Retina 35 (8), 1489-1506, 2015 | 264 | 2015 |
| Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study Y Ikuno, K Ohno-Matsui, TY Wong, JF Korobelnik, R Vitti, T Li, B Stemper, ... Ophthalmology 122 (6), 1220-1227, 2015 | 227 | 2015 |
| Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab: post hoc review of HAWK and HARRIER J Monés, SK Srivastava, GJ Jaffe, R Tadayoni, TA Albini, PK Kaiser, ... Ophthalmology 128 (7), 1050-1059, 2021 | 212 | 2021 |
| Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study Y Ogura, J Roider, JF Korobelnik, FG Holz, C Simader, U Schmidt-Erfurth, ... American journal of ophthalmology 158 (5), 1032-1038. e2, 2014 | 188 | 2014 |
| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two … CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ... The Lancet 399 (10326), 741-755, 2022 | 170 | 2022 |
| Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery MN Delyfer, MB Rougier, S Leoni, Q Zhang, F Dalbon, J Colin, ... Journal of Cataract & Refractive Surgery 37 (2), 271-278, 2011 | 145 | 2011 |
| Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study JF Korobelnik, D Hannouche, N Belayachi, M Branger, JE Guez, ... Ophthalmology 103 (4), 590-594, 1996 | 139 | 1996 |
